United-Guardian, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. United-Guardian develops, manufactures, and markets personal care, pharmaceutical, medical, and specialty industrial products. Approximately 70% of products are sold to end users outside the U.S.; Ashland Specialty Ingredients is its largest marketing partner.
Financial performance
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Net sales | $3.959 million | $3.952 million | +0.2% |
| Income from operations | $1.911 million | $1.979 million | -3.5% |
| Income before taxes | $1.969 million | $2.326 million | -15.4% |
| Net income | $1.336 million | $1.565 million | -14.6% |
| Basic and diluted EPS | $0.29 | $0.34 | Down $0.05 |
| Cash from operations | $892,212 | $2.064 million | Down $1.172 million |
Gross margin was approximately 63.8%, versus 64.3% a year earlier; operating margin was approximately 48.3%, versus 50.1%; net margin was approximately 33.7%, versus 39.6%. Cost of sales rose to 36.2% of sales from 35.7%, primarily due to product mix. Operating expenses increased 9.6% to $616,000, mainly from higher insurance and utility costs.
At March 31, cash and cash equivalents were $973,186 and marketable securities were $10.485 million. Working capital was $14.500 million, up from $13.062 million at year-end; the current ratio was 9.6:1, down from 11.5:1. Accounts receivable increased to $2.689 million from $1.791 million, and average collection time rose to 51 days from 34 days. Total liabilities were $1.886 million; the balance sheet reports no borrowings. No financing cash flows were reported. Cash and equivalents fell $661,076 during the quarter, while marketable securities increased to $10.485 million from $8.863 million.
Material changes and unusual items
- Personal care gross sales rose $102,765 (3.4%), including an 8.7% increase in sales to the largest marketing partner, partly offset by declines at other partners.
- Pharmaceutical gross sales increased $229,566 (211.1%) as RENACIDIN sales resumed in late October 2013 after a prolonged supplier production curtailment. RENACIDIN sales remained below historical levels.
- Medical product sales declined $308,558 (35.5%), which management attributed mainly to order timing. Industrial and other product sales decreased $9,088 (21.2%).
- Other income fell to $58,221 from $347,012, principally because RENACIDIN supplier settlement income declined to $24,402 from $292,830. The final ramp-up payment was received in Q1 2014; all settlement payments had been made by quarter-end.
- Operating cash flow was lower, reflecting lower earnings and working-capital movements, including the increase in receivables. Investing cash outflow was $1.553 million, mainly reflecting purchases of marketable securities.
- Unrealized gains on marketable securities produced $58,633 of other comprehensive income, net of tax. The company reported no dividends paid in either comparative quarter.
Outlook, risks, and other matters
Management believes working capital will support operating needs for at least the next 12 months and expects no significant capital expenditures for the remainder of 2014. It expects to continue using cash for dividends, marketable securities, and other opportunities. The company anticipates a new single-dose RENACIDIN form may reach the market in early 2015, subject to FDA approval; delays could affect timing. Management expects the effective tax rate to remain approximately 32% for 2014.
Risks identified include competition and product acceptance, product development and quality, intellectual property, economic and industry conditions, regulation, interest rates, securities markets, and the company’s ability to raise capital. A New York State tax examination of 2010–2012 returns began in March 2014; the filing reports no unrecognized tax benefits. No legal proceedings or off-balance-sheet arrangements were reported. Management assessed disclosure controls as effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether RENACIDIN supply, sales recovery, and FDA approval for the proposed single-dose product meet management’s expectations.
- Whether the higher receivables balance and 51-day collection period convert to cash as expected, especially for foreign customers.
- How product mix and sales to the largest marketing partner affect margins and future revenue; headline sales were nearly flat despite substantial category shifts.
- How results develop after the final supplier settlement payment, which materially supported prior-year comparative other income.
- Whether the New York State tax examination or other disclosed risks lead to material changes; the filing provides no quantified potential exposure.